Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MD
MD logo

MD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
21.260
Open
20.990
VWAP
20.26
Vol
637.08K
Mkt Cap
1.86B
Low
19.690
Amount
12.90M
EV/EBITDA(TTM)
7.75
Total Shares
83.07M
EV
1.96B
EV/OCF(TTM)
7.13
P/S(TTM)
1.00
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Show More

Events Timeline

(ET)
2026-05-05
06:20:00
Pediatrix Medical Reaffirms FY26 Adjusted EBITDA View of $280M-$300M
select
2026-05-05
06:10:00
Pediatrix Medical Group Q1 Revenue Reaches $476M
select
2026-02-19 (ET)
2026-02-19
06:20:00
Pediatrix Medical Sees FY26 Adjusted EBITDA of $280M-$300M
select
2026-02-19
06:20:00
Pediatrix Medical Group Reports Q4 Revenue of $494M
select

News

moomoo
9.5
05-05moomoo
PinnedPediatrix Medical Group Reports Q1 Revenue of $476.196 Million, Exceeding IBES Estimate of $465.8 Million
  • Pediatrix Medical Group Revenue: Pediatrix Medical Group reported a revenue of USD 476.196 million for Q1.
  • Comparison with Estimates: This revenue figure exceeds the estimates from IBES, which were USD 465.8 million.
seekingalpha
9.5
05-04seekingalpha
PinnedPediatrix Medical Group Q1 Earnings Announcement Scheduled
  • Earnings Release Date: Pediatrix Medical Group is set to announce its Q1 earnings on May 5 before market open, with a consensus EPS estimate of $0.38, reflecting a 15.2% year-over-year growth, indicating robust profitability trends.
  • Revenue Expectations: The anticipated Q1 revenue is $465.82 million, representing a 1.6% year-over-year increase, which, while modest, still demonstrates ongoing demand and stability in the healthcare services sector.
  • Historical Performance: Over the past two years, Pediatrix has beaten EPS estimates 88% of the time and revenue estimates 75% of the time, a strong performance record that may bolster investor confidence ahead of the earnings announcement.
  • Future Outlook: The company anticipates adjusted EBITDA of $280 million to $300 million in 2026, focusing on practice alignment and telemedicine, indicating a proactive approach to adapting to evolving trends in the healthcare industry.
seekingalpha
9.5
05-05seekingalpha
Pediatrix Medical Group Q1 2026 Earnings Call Insights
  • Strong Financial Performance: Pediatrix Medical Group reported an adjusted EBITDA of $58 million for Q1 2026, reflecting a decline from $66 million in the previous quarter, yet demonstrating robust revenue growth that indicates stability in the market.
  • Revenue Growth Drivers: The company noted a same-unit growth of nearly 3% and net non-same unit activity contributing about $6 million, despite some revenue declines due to portfolio restructuring, showcasing the potential from acquisitions and organic growth.
  • Cash Flow and Capital Management: In Q1, the company utilized $130 million in operating cash flow and deployed $21 million in capital to repurchase 1 million shares, indicating a proactive approach to capital management while maintaining over $200 million in cash reserves and $385 million in net debt.
  • Future Outlook and Challenges: Management reaffirmed the adjusted EBITDA outlook for 2026 at $280 million to $300 million, acknowledging potential risks from declining patient volumes and revenues in hospital systems, yet expressing optimism about stability and emphasizing the need to remain cautious regarding subsidy impacts.
moomoo
7.5
05-05moomoo
Pediatrix Medical Group Reports Q1 Operating Expenses of $434.539 Million
  • Financial Overview: PediaTric Medical Group reported operating expenses totaling USD 434.539 million for Q1.
  • Budget Implications: The significant operating expenses may impact future financial planning and resource allocation for the organization.
Newsfilter
7.5
03-26Newsfilter
Pediatrix Expands Maternal-Fetal Care in Tennessee
  • Service Expansion: Pediatrix Medical Group enhances its service network in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine, ensuring high-quality maternal-fetal care for expectant mothers in the Greater Nashville area and strengthening its market position in this sector.
  • Expert Team: The practice comprises four board-certified physicians and six advanced practice providers, offering comprehensive maternal-fetal medicine services, thereby enhancing Pediatrix's ability to meet the growing maternal care needs in Middle Tennessee.
  • Strategic Partnership: This collaboration not only elevates Pediatrix's specialty services but also integrates the national reputation of Tennessee Maternal-Fetal Medicine, which is expected to positively impact the company's future revenue streams.
  • Financial Impact: The transaction is a cash deal and is anticipated to be immediately accretive to Pediatrix's earnings, further solidifying its leadership position in the maternal-fetal medicine market.
Newsfilter
5.0
03-24Newsfilter
Pediatrix Appoints Two Quality Care Experts
  • Executive Appointments: Pediatrix Medical Group has announced the appointment of Dr. James Barry as Chief Clinical Quality & Transformation Officer and Dr. Jochen Profit as Chief Quality Advisor, both renowned for their expertise in care quality, which is expected to enhance the company's service quality for women, babies, and children.
  • Quality Improvement Strategy: Dr. Barry will be responsible for shaping the medical direction of the organization, ensuring the highest standards of patient care, and overseeing the work of the Pediatrix Center for Research, Education, Quality and Safety, aimed at improving patient experience and reducing healthcare costs through clinical research and continuous quality improvement.
  • Innovation and Leadership: Dr. Barry's contributions in neonatal critical care and medical artificial intelligence will provide strategic advantages for Pediatrix, as his experience will help the company maintain competitiveness in a rapidly evolving healthcare environment.
  • Research and Optimization: Dr. Profit's research on optimizing care delivery for pregnant individuals and newborns will provide expert guidance for Pediatrix, advancing the company's efforts in health equity and family-centered care, thereby enhancing patient safety and care quality.
Wall Street analysts forecast MD stock price to rise
3 Analyst Rating
Wall Street analysts forecast MD stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
23.00
Averages
23.50
High
24.00
Current: 0.000
sliders
Low
23.00
Averages
23.50
High
24.00
Jefferies
Jack Slevin
Buy
maintain
$24 -> $27
AI Analysis
2026-04-20
Reason
Jefferies
Jack Slevin
Price Target
$24 -> $27
AI Analysis
2026-04-20
maintain
Buy
Reason
Jefferies analyst Jack Slevin raised the firm's price target on Pediatrix Medical to $27 from $24 and keeps a Buy rating on the shares. The relative underperformance of healthcare services stocks highlights concerns among investors about Q1 volumes, notes the analyst, who is "unsure if Street numbers adequately reflect" drags from ice storms in Southern states and snow storms in the East Coast that impacted volumes.
Truist
Hold
maintain
$21 -> $23
2026-04-13
Reason
Truist
Price Target
$21 -> $23
2026-04-13
maintain
Hold
Reason
Truist raised the firm's price target on Pediatrix Medical to $23 from $21 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services, or HC. The firm remains broadly bullish on its HC Services coverage universe tied to continued strong demand trends, overarching secular tailwinds and more favorable/stable reimbursement backdrop, with the recent Final Medicare Advantage Rule seen as an "encouraging data point", the analyst tells investors in a research note. Truist adds that it continues to think the sector is well positioned given that it's scaled, domestic and defensive, also noting that the group is a beneficiary of AI/automation/interconnectivity, with strong free cash flow and attractive financial flexibility supporting the ongoing growth investment/M&A/shareholder friendly initiatives.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Pediatrix Medical Group Inc (MD.N) is 8.21, compared to its 5-year average forward P/E of 10.40. For a more detailed relative valuation and DCF analysis to assess Pediatrix Medical Group Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
10.40
Current PE
8.21
Overvalued PE
14.20
Undervalued PE
6.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.31
Current EV/EBITDA
9.03
Overvalued EV/EBITDA
10.43
Undervalued EV/EBITDA
6.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.74
Current PS
0.95
Overvalued PS
1.05
Undervalued PS
0.44

Financials

AI Analysis
Annual
Quarterly

Whales Holding MD

D
Dana Investment Advisors Inc
Holding
MD
+5.88%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Pediatrix Medical Group Inc (MD) stock price today?

The current price of MD is 19.815 USD — it has decreased -11.58

What is Pediatrix Medical Group Inc (MD)'s business?

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

What is the price predicton of MD Stock?

Wall Street analysts forecast MD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is23.50 USD with a low forecast of 23.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pediatrix Medical Group Inc (MD)'s revenue for the last quarter?

Pediatrix Medical Group Inc revenue for the last quarter amounts to 493.77M USD, decreased -1.71

What is Pediatrix Medical Group Inc (MD)'s earnings per share (EPS) for the last quarter?

Pediatrix Medical Group Inc. EPS for the last quarter amounts to 0.40 USD, increased 11.11

How many employees does Pediatrix Medical Group Inc (MD). have?

Pediatrix Medical Group Inc (MD) has 2295 emplpoyees as of May 06 2026.

What is Pediatrix Medical Group Inc (MD) market cap?

Today MD has the market capitalization of 1.86B USD.